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Approximately 195,000 people in the United
States underwent long-term dialysis in 1995, as
compared with 150,650 in 1992, and more than
80% of these patients underwent hemodialysis.1 As
the prevalence of renal failure has increased, more
dialysis graft placements and revisions are necessary
to maintain hemo-access.1,2 The population under-
going dialysis is older, has more comorbidity, and is
less likely to have suitable veins for autogenous
access. In our center, despite a preference for auto-
genous fistulae, two thirds of the new hemodialysis
access constructions are prosthetic bridge grafts
caused by poor vein quality and the need for reliable
access in patients with marginal veins. Thrombosis is
a frequent occurrence in prosthetic grafts, with 1-
year primary patency rates ranging from 63% to 74%
in current reports.3,4
Most graft thrombosis episodes coincide with
the development of stenosis. These lesions are at or
near the venous anastomosis in 58% to 90% of the
patients and are usually caused by neointimal hyper-
plasia.5-8 The traditional treatment has been surgical
thrombectomy and local revision, although the
long-term patency with this approach has been dis-
appointing with 1-year primary patency rates of 3%
to 36%.3,9,10 In the past decade, improvements in
Endovascular versus surgical treatment for
thrombosed hemodialysis grafts: 
A prospective, randomized study
Matthew J. Dougherty, MD, Keith D. Calligaro, MD, Nancy Schindler, MD,
Carol A. Raviola, MD, and Adu Ntoso, MD, Philadelphia, Pa
Purpose: The objective of this study was to compare clinical outcome and costs for two
widely used treatment strategies for hemodialysis graft thrombosis.
Methods: During a 4-year period, 80 patients with thrombosed dialysis grafts were ran-
domly assigned to surgical thrombectomy with or without graft revision (SURG) or
thrombolytic therapy with urokinase with the pulse-spray technique (ENDO), with
adjunctive percutaneous transluminal angioplasty as indicated. All the procedures were
performed in an endovascular operating suite with fistulography. The clinical and cost
data were tabulated, and the outcome was analyzed with the life-table method.
Results: Fifty-six women and 24 men ranged in age from 33 to 90 years (mean, 63.7
years). The patients had undergone a mean of 2.8 prior access procedures in the ipsilat-
eral extremity. All the grafts were upper extremity expanded polytetrafluoroethylene
grafts. Lesions that were presumed to be the primary cause of graft thrombosis were
identified in 73 of 80 grafts, and 60 of these were at the venous anastomosis. The pro-
cedure time averaged 99 minutes for the patients in the SURG group and 113 minutes
for the patients in the ENDO group (P = .12). Eleven patients in the ENDO group
crossed over to surgical revision as compared with two patients in the SURG group who
required adjunctive percutaneous transluminal angioplasty (P = .005). The mean cost of
treatment (including room and supply costs but not professional fees) was significantly
higher for the ENDO group than for the SURG group ($2945 vs $1512; P < .001).
There were no procedure-related complications in either group. At a median follow-up
time of 24 months, there was no difference in primary or assisted primary patency
between groups, which averaged 6 and 7 months, respectively.
Conclusion: Although thrombolytic therapy combined with endovascular treatment can
extend the life of dialysis grafts with results similar to surgical revision, there is a high
rate of technical failure necessitating surgery and a substantially higher cost for throm-
bolysis. (J Vasc Surg 1999;30:1016-23.)
From the Section of Vascular Surgery, Section of Nephrology (Dr
Ntoso), Pennsylvania Hospital, University of Pennsylvania.
Presented at the Thirteenth Annual Meeting of the Eastern
Vascular Society, Pittsburgh, Pa, Apr 30–May 2, 1999.
Reprint requests: Dr Matthew J. Dougherty, 700 Spruce St, Ste
#101, Philadelphia, PA 19106.
Copyright © 1999 by the Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/99/$8.00 + 0 24/6/101473
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 6 Dougherty et al 1017
endovascular technologies have provided a potential
new treatment strategy and comparable patency
rates have been reported.6,7,11
To address this issue, we performed a prospec-
tive, randomized study to compare endovascular 
and surgical treatment for thrombosed prosthetic
arteriovenous hemodialysis grafts (AVG) with regard
to outcome and cost.
MATERIALS AND METHODS
A protocol for patients with dialysis access graft
thrombosis was developed and was approved by 
the Research Review Committee at Pennsylvania
Hospital. After giving informed consent, the patients
were randomly assigned to one of two treatment
groups. The patients for surgical treatment (SURG)
underwent graft exploration and thrombectomy, and
any stenosis that was identified was treated with
patch angioplasty or interposition or bypass graft-
ing. Intraoperative fistulography was routinely per-
formed. The patients for endovascular treatment
(ENDO) were treated with a method previously
described by other investigators.8 The AVG was
accessed, and two 5F sheaths were placed to allow for
the cross positioning of two pulse-spray catheters
(AngioDynamics Inc, Queensbury, NY) through the
entire graft length and across the arterial and venous
anastomoses. Systemic heparin therapy (3000 units)
was administered. Urokinase (Abbott Laboratories,
North Chicago, Ill) was vigorously infused (250,000
units with 10,000 units heparin divided between two
10-mL syringes) with 0.25 mL every 30 seconds 
for 20 minutes. The graft was vigorously massaged
throughout the infusion period to maximize the
clot/drug exposure. Embolectomy catheters were
passed under direct visualization across both anasto-
moses, and fistulography was performed. The identi-
fied stenoses were treated with percutaneous balloon
angioplasty. Residual thrombus could also be treated
with balloon maceration, and, if deemed necessary,
the protocol permitted a second urokinase infusion
(250,000 units) to treat residual clot. All the proce-
dures were performed with local anesthesia and intra-
venous sedation in an endovascular operating room
that was equipped with digital imaging.
The exclusion criteria included contrast allergy,
urokinase allergy, bleeding diatheses, graft infection,
history of significant gastrointesinal hemorrhage, any
prior cerebral or ocular hemorrhage, major surgery
within the prior 3 months, or ipsilateral dialysis access
surgery within the prior 4 weeks. Although approx-
imately half of all the patients with thrombosed dial-
ysis grafts had contraindications to lytic therapy, only
four eligible patients declined randomization during
the study period.
The patients in the ENDO group were consid-
ered to have crossed treatment groups if surgical
incisions were necessary. The patients in the SURG
group were considered to have crossed over if bal-
loon angioplasty was used.
The patient demographic and clinical factors
were tabulated along with the graft features and
angiographic findings. The procedure-related costs,
which included operating room time but excluded
professional fees, were recorded. The outcome mea-
sures that were defined included the procedure-
related complications and their costs and the end
points of cumulative primary and assisted primary
patency.12 The groups were compared for dichoto-
mous variables with the Pearson c 2 test and for con-
tinuous factors with the Student t test. The patency
outcomes were calculated with the Kaplan Meier
life-table method and compared for groups with the
log-rank test. Analysis was performed on an inten-
tion-to-treat basis, with secondary analysis per-
formed to exclude cross-over patients.
RESULTS
Eighty patients were randomized between
November 15, 1994, and August 15, 1998, to sur-
gical (SURG, n = 41) or endovascular (ENDO, n =
39) treatment. Fifty-six women and 24 men ranged
in age from 33 to 90 years (mean, 63.7 years). The
gender proportions reflected the composition of
the dialysis unit at Pennsylvania Hospital. Renal
failure was caused by hypertension in 41 patients,
diabetes mellitus in 16 patients, and other factors
in the remaining patients (Table I). The patients
had been undergoing hemodialysis for a mean of
35.3 months and had undergone a mean of 2.8
prior ipsilateral access revisions. An average of 7.5
months had elapsed since a prior ipsilateral proce-
dure. All grafts were upper extremity polytetrafluo-
roethylene grafts: 39 were completely distal to the
antecubital crease, 31 were completely proximal,
and 10 were crossing the joint.
There was no difference in the aforementioned fac-
tors between the two randomly assigned groups,
except that the patients in the SURG group were older
(67.9 ± 15.1 years vs 59.2 ± 15.4 years; P = .013).
Seventy-three of 80 grafts were found to have a
stenosis that was believed to be the primary cause of
graft failure (Table II). In the patients in the SURG
group with stenoses, the primary lesions were treat-
ed with patching (n = 14), with graft interposition or
bypass grafting (n = 17), or with graft curettage for
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midgraft lesions (n = 6). In the patients in the
ENDO group, all the lesions were treated with 
balloon angioplasty, with two patients undergoing
adjunctive stent placement. The primary lesion 
was at the venous anastomosis in 60 of 73 grafts
(82.2%), and 16 patients in the SURG group and 18
patients in the ENDO group had more than one
lesion treated. For all the stenoses treated, 78 of 110
(70.9%) were at the venous anastomosis or the main
outflow vein.
Eleven patients in the ENDO group (28.2%)
required surgical revision, and only two patients in
the SURG group (4.9%) required adjunctive balloon
angioplasty—a significant difference in cross over (P
= .005). The reasons for crossing treatment groups
are listed in Table III.
Aside from early graft thrombosis, which is
reflected in patency rate calculations, there were no
procedure-related complications that required treat-
ment in either group.
The cumulative primary and assisted primary
patency rates are shown in Fig 1, with a median fol-
low-up period of 24 months (standard error, <10%
through 36 months). The primary patency rate at 12
months was 26.0% ± 7.6% for the SURG group and
13.7% ± 6.6% for the ENDO group (log-rank test, P
= .78). The assisted primary patency rate figures were
43.3% ± 8.2% and 21.4% ± 7.7%, respectively (log-
rank test, P = .47). The secondary patency rate was
not analyzed. The median time to graft rethrombosis
was 7 months for the SURG group as compared with
6 months for the ENDO group (P = NS).
The cost data are summarized in Table IV. The
mean cost of treatment was significantly higher for
the ENDO group ($2945 vs $1512; P < .001). The
exclusion of cross-over patients from the analysis
reduced procedure-time related costs, but signifi-
cantly higher overall costs persisted ($2663 vs
$1538; P < .001).
Fig 1. Primary patency and assisted primary patency life
tables by group.
Table I. Distribution of preoperative features
between groups
Features Surgery Endovascular
Female gender 30 (73%) 26 (67%)
African American 33 (80%) 28 (72%)
Cause of renal failure
Diabetes mellitus 11 (27%) 5 (13%)
Hypertension 18 (44%) 23 (59%)
Other 12 (29%) 11 (28%)
Graft type
Forearm 20 (49%) 19 (49%)
Upper arm 18 (44%) 13 (33%)
Across elbow 3 (7%) 7 (18%)
Prior revisions in same arm 3.02 2.51
Months since last ipsilateral operation 8.4 6.0
Months on dialysis 37 33
Mean age (years)* 67.9 59.2
No differences were noted between groups, except for age.
*P = .013.
Table II. Location of the primary lesion treated
Primary lesion Surgery Endovascular
None 4 (10%) 3 (8%)
Artery 1 (2%) 0 (0%)
Within graft 6 (15%) 2 (5%)
Venous anastomosis 28 (68%) 32 (82%)
Outflow vein 2 (5%) 2 (5%)
A
B
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DISCUSSION
The use of thrombolytic therapy combined with
angioplasty to restore the patency of occluded hemo-
dialysis access grafts was first reported in 1983.13 In
earlier reports, the thrombolytic agents were infused
with techniques similar to those used for thrombosed
arterial grafts, via a slow infusion through a single
catheter. The need for intensive care unit monitoring,
the prolonged time to complete lysis, and the fre-
quent complications limited the acceptance of this
approach.6,14 The methods that accelerated the lytic
process via “pharmacomechanical” means7 have al-
lowed complete treatment in a single setting, with
adjunctive use of balloon angioplasty to treat causal
lesions, and this has been adopted as a primary
approach to thrombosed dialysis grafts in a number
of centers.8
Given the highly variable and generally poor
reported patency rates of AVG revision,3,9,10,15,16
which may be related to the patient populations at
individual centers, comparisons between competing
therapies with retrospective data are difficult. Two
prospective randomized studies that compared the
surgical and endovascular treatments of thrombosed
AVG have been reported. Although the report from
Veseley et al17 included only 20 patients, the authors
could demonstrate no difference between surgery
and endovascular treatment in either cost or patency
rate. The 6-month secondary patency rate was only
20% for surgery and 10% for thrombolysis.17 The
larger study from Marston et al10 included 115
patients but reported a disappointing primary paten-
cy rate at 6 months of 36% for patients for surgery as
compared with 11% for patients for endovascular
treatment, a difference that was statistically signifi-
cant. No differences were found for costs.10
Given the high reported rates of initial technical
failure (29% to 41%) with endovascular treat-
ment,10,14,18 we elected to perform all procedures in
an endovascular operating suite so that immediate sur-
gical revision could be performed when necessary.
Although an operating room must be used for surgical
treatment and an angiography suite might suffice for
endovascular therapy, we believed that the resources
were comparable (in terms of staffing, equipment,
etc). No patient was administered general anesthesia,
and local anesthesia and intravenous sedation were
routinely used in both settings. Completion fistulogra-
phy was used in both cohorts, which may have added
costs to the SURG group because many surgeons omit
this, but we believed this was important to document
technical success in revisions performed with either
method. Because many patients with chronic renal 
failure have multiple comorbidities, our cost analysis
was limited to costs that were specifically associated
with the declotting procedure and the complications
thereof.
We did not analyze secondary patency rates
because with an aggressive approach to maintaining
previously placed grafts and avoiding catheter dialysis,
many patients undergo multiple revisions. The differ-
entiation of a “revised old graft” from a substantially
newer graft can be difficult, and the abandonment of
a thrombosed graft for a new access at another site
reflects a surgeon’s philosophy more than the success
of a particular intervention. The mean primary and
assisted primary patency rates were in the range of 6
months in both the ENDO and SURG groups. The
slight trend toward a better patency rate in the SURG
group did not reach statistical significance.
The high cross-over rate in our study for the
ENDO group (11 of 39; 28.2%), although similar to
technical failure rates in other reports,10,14,19 may
reflect the surgeon’s cognizance of procedure time as
a factor being analyzed and the protocol-established
limits on urokinase amounts. Most other reports have
excluded immediate failures from patency rate analysis.
Although we believe that the exclusion of immediate
failures is misleading in the assessment of results, we
questioned whether the frequent need for cross over
may have masked an important difference in patency
Table III. Reasons for crossing treatment groups
Cross-over reason Surgery Endovascular
Bleeding 0 4
Persistent stenosis 0 3
Residual thrombus 0 3
Arterial embolism 0 1
Lesion difficult to access 2 0
Endovascular group crossed over more frequently (P = .005).
Table IV. Time and cost analysis
Time and costs Surgery Endovascular
Operating room time 99 (99) 113 (94)
(minutes)
Operating room time $1288 ($1323) $1452 ($1180)
cost
Supply costs $224 ($214) $1492 ($1483)
Total costs $1512 ($1537) $2945 ($2663)
Figures in parentheses exclude cross-over patients. In both com-
parisons, surgery supply and total costs are significantly lower 
(P < .001).
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rate. A secondary Kaplan-Meier analysis was therefore
performed to exclude the patients who crossed treat-
ment groups, and the patency rates did not change.
Thus we conclude that although long-term success is
limited with both approaches, the patency rates for the
patients who undergo treatment with endovascular
therapy are comparable with the rates for the patients
who undergo surgical treatment.
The most substantial contribution to a cost differ-
ence might have been significant differences in paten-
cy or complication rates because the need for repeat-
ed procedures would likely overwhelm the moderate
per-procedure costs, as could excess hospital days and
other costs of the treatment of complications. Because
we found no patency rate difference and because
(aside from early thrombosis) there were no proce-
dure-related complications in either cohort, all the
differences reflect the procedure itself. We demon-
strated a highly significant increased cost for endovas-
cular treatment as compared with surgery. The major
components of this cost analysis were supply costs and
increased procedure time. When we reanalyzed the
data after the exclusion of patients with technical fail-
ure who crossed treatment groups, there was no sig-
nificant difference in procedure time, but the higher
supply and overall costs remained (Table IV).
Changes in technology, in costs of supplies, and in
other factors may alter the dynamic in favor of
endovascular treatment. However, newer devices may
in fact prove to be more expensive than the materials
used in this study. To date, no prospective study has
shown superior patency rates or lower costs for
endovascular treatment as compared with surgery.
Unless newer technologies actually improve patency
rates or markedly diminish procedure times, substan-
tial cost savings are unlikely. Although endovascular
treatment avoids a small incision, it currently does not
offer superior results, and it costs more. Our current
practice is to reserve endovascular treatment for situ-
ations in which operative exposure may be unusually
difficult or morbid, such as treatment high in the axil-
la in obese patients or in the setting of nonhealed
wounds. However, given the poor long-term results
with both surgical and endovascular treatment for
dialysis graft thrombosis, more diligent efforts should
be made at early construction of autogenous fistula to
avoid the need for prosthetic grafts when possible.
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Dr Michael B. Silva, Jr (Newark, NJ). I am pleased to
have the opportunity to discuss this interesting manuscript.
In this study, the authors have added their voices to
the ongoing debate over the appropriate method for treat-
ing the failed dialysis access graft. They are to be compli-
mented for their study design, which uses a prospective
randomization protocol to examine the efficacy and cost
associated with two popular methods, surgical thrombec-
tomy with adjunctive surgical revision of the offending
lesion and lytic therapy with a cross-catheter pharmaco-
mechanical technique for reestablishing patency in throm-
bosed dialysis bridging grafts. The authors performed all
of these procedures with local anesthesia within an
endovascular operating suite venue.
Of note, the authors suggest that the need for maxi-
mizing options for dialysis access is driven by the increase
in survival of patients on dialysis. In fact, a review of the
information provided by the US Renal Data System sug-
gests that patient survival may have actually decreased and
currently averages just over 5 years for all patients under-
going dialysis. It is true, however, that more patients are
undergoing dialysis, that they are older, and that they have
more comorbid conditions. Given the significant expense
of maintaining a functioning access site in this population,
their comparison and the questions implied are valid ones.
I have a number of questions for the authors regard-
ing this interesting study. First, the authors state in Table
I that at the start of the study the surgery group had an
average of 3 prior grafts in the same arm and the endovas-
cular group had an average of 2.5. However, in the Results
section, the authors state that the group as a whole had an
average of 2.8 prior ipsilateral access procedures. Please
clarify this for me. Were these salvage procedures per-
formed on grafts that had previously been revised, or were
these the initial failure rates for a graft placed in an arm
with a prior history of other failed grafts? In other words,
did you differentiate between the number of previously
failed grafts and the number of revisions to existing grafts
in the same arm? If one group had a higher rate of previ-
ous revisions, one might predict a worse outcome for the
current attempt at salvage.
Were any of these patients entered into the study
twice? Did you account for this in your analysis?
You report assisted patency rates for both groups as
being equivalent, even though the numbers were 43% for the
surgery group and 21% for the endovascular group at 12
months. What were your criteria for a failing graft that would
prompt additional intervention? Were the assisting interven-
tions performed endovascularly or surgically? Were there
cross-overs between the groups included in your study?
As to the issue of your attempted cost analysis, please
define how you determined cost. Were these charges, reim-
bursements, or actual hospital costs for performing the pro-
cedures? Why not include the physician charges as a part of
the overall cost of the procedure? There are a number of
ways to accurately code and charge for endovascular graft
salvage that invariably arrive at amounts in excess of surgical
thrombectomy and revision charges. What do you code for
when you open a graft with the endovascular method?
Your bridging graft placement rate of 66% is in excess
of the DOQI recommended guidelines. Have you been
evaluating your patients with duplex ultrasound scanning
to increase your rate of autogenous fistula formation?
Finally, with primary patency rates of approximately
30% at 180 days, are either surgical or endovascular sal-
vage procedures justifiable? Or should we seriously con-
sider abandoning attempted salvage and proceed with new
graft placement?
I would like to thank the authors for providing this
manuscript to me for advanced review and the Society for
the privilege of participating in the review process.
Dr Matthew J. Dougherty. Thank you, Dr Silva.
With regard to the first question on prior procedures
in these patients, this included all the surgical revisions of
a graft or subsequent placement of a new graft in the same
arm. This question reflects the same problem that we had
when we tried to look at secondary patency rates here.
These patients tend to have a lot of different things done
to the grafts, and we simply classified them as procedures
and hoped that the randomization process would even
that out.
Regarding your second question, there were about a
half dozen patients who were entered more than once,
either with grafts in the other arm or in the same arm. We
believed that this methodology was reasonable as long as
they were still being assigned randomly. In terms of the
demographics and graft features, this methodology prob-
ably increased slightly the average number of previous
procedures than we might see if we had only allowed
patients to be entered once.
Your next question was regarding the patency results.
Because our numbers are very similar to the numbers in
the trial of Marston et al,10 if we had 20 or 30 more
patients, would we in fact have been able to discern a bet-
ter outcome in the patients for surgery? All I can tell you
is, on the basis of log-rank comparison rather than looking
at patency at one particular time, those results were not
significantly different. I will say that most of the assisted
patency procedures were balloon angioplasty, and that var-
ied in number. Some patients had as many as two or three
balloon angioplasties performed. That is done at the dis-
cretion of the nephrologist and radiologist. They follow
Kt/V and ultrasonic flow determinations and have a fairly
liberal attitude towards obtaining a fistulogram if they are
not happy with the graft.
As far as the cost analysis, this is very tricky, as you
know, and we tried to make this as pure a comparison as
possible. We looked at costs, not charges. The costs in our
hospital accounting system are pretty much a multiplier on
the basis of hospital charges, in the range of 55%.
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In terms of professional fees, I think when we are
focusing on cost, it is more useful to really look at actual
professional time spent, because current procedural termi-
nology (CPT) coding can be quite variable. When you look
at the operating room time, I think that is probably a pret-
ty good assessment of the amount of effort expended by
the professional, whether an angiographer or a surgeon.
The next question was regarding the use of bridge
grafts. Unfortunately, we do not tend to have these patients
referred early on, and often they need to undergo dialysis
immediately. We have a choice of either placing a graft or
using a central catheter, which has its own problems, for a
prolonged period while we wait for a primary fistula to
mature. We are, however, changing our policy, after having
reviewed our data here, and we are now trying to be far
more aggressive with the use of autogenous fistulae. In fact,
we are now constructing a primary fistula in the other arm
at the same time that we are placing a bridge, because with
these kinds of results you can plan on needing it.
You asked about the primary patency rate of 30% at
180 days. It is a little closer to 45%. But if you take it out
to a year, the rate is pretty pitiful. And I think you are
absolutely correct when you question whether this is
worthwhile. The problem is that these patients need to
undergo dialysis immediately, and if you decide to put in a
new graft each time, then you are going to be putting in a
lot of central catheters, which can cause more problems
down the line. However, I think that in terms of trying to
proceed with these patients early on while they still have
good veins, with a primary fistula, that is probably the way
to go.
Dr John J. Ricotta (Stony Brook, NY). I would just
like to ask you a couple of questions. I might have missed
it, but it sounded like there were multiple lesions in each
of these grafts or in a significant number of the grafts.
How many of the grafts had multiple lesions? Do you have
any idea of how old these grafts were from the time they
were initially placed and where the multiple lesions are? At
some point you have to decide that something that is
being poked three times a week for a year and a half and
clots off is just not going to be worth fixing. Do you have
any idea? Were the lesions in the graft? Were they proximal
venous lesions? Were they arterial lesions? And how did
that correlate with the patency rate?
Dr Dougherty. We basically classified the primary
lesions. So, we had to select what we thought really caused
the graft to clot, and then we also listed secondary lesions,
if they were treated. About 50% of the patients had at least
one secondary lesion. A lot of those were mid-graft
lesions. In the endovascular group, there were more arte-
rial lesions, as you may have noticed in the Table, because
I think that the platelet plug that sits at the artery is pret-
ty hard to lyse.
In terms of whether these really represent old, worn-
out grafts with lots of fibrous ingrowth and that sort of
thing, that is not the case. I think the average graft was
about a year and a half old. They were not really old grafts.
There were a few that were, but, again, not the majority.
Dr Enrico Ascher (Brooklyn, NY). This is a very inter-
esting study, and it was very well presented. I wonder,
though, whether this data can only be used for surgeons
to learn from it, rather than used to convince our hospital
administrator that this procedure has to be done in the
operating room and not in the radiologist suite. So, I do
not think that the cost assessment that you have shown is
really going to help us when we go and present the data
for the operation room versus the radiologic suite proce-
dures, because you are performing this operation in the
operating room. So, I wonder what is your thinking about
that part of this study and its impact on our “dispute” with
the radiologists? That is question number one.
Number two. I am sure by now that you are somewhat
discouraged with these thrombectomies and redo opera-
tions that are not getting us anywhere. Have you consid-
ered using a duplex scanning procedure to look at the
alternatives to thrombectomy, such as using the cephalic
or the basilic in the arm as a better procedure for redo
operations? That is basically what the DOQI study is rec-
ommending, and we are about to present our data at the
Society for Vascular Surgery meeting next month. Our
data show that these operations are certainly better than
thrombectomies.
Dr Dougherty. Thank you. As far as your first question,
I actually did try to perform a second analysis, because I
figured somebody would comment, “Well, if you did this
in the radiology suite, maybe that would be cheaper.” It is
very hard to get the data on the cost of the radiology suite.
They do not have any sort of time-associated charge or cost
data. They basically bill by the procedure.
We believed that because all of these procedures were
being done with local anesthesia with intravenous sedation
in a similar fashion to what is done in the radiology suite,
that really the level of expertise needed in either setting
was pretty similar. In fact, I would make the opposite
argument, which is that if you do this in the radiology
suite and it fails—which in 30% to 40% of patients in the
published series they do—then you have a patient who
needs dialysis, probably cannot go home until something
is done, and then needs to go to the operating room
maybe the next day. And that is certainly going to add to
the costs.
Regarding your second question, I think we absolute-
ly are trying to take a more aggressive stance in terms of
finding adequate veins for primary fistulae. We have just
started using ultrasound scanning procedures. To be per-
fectly honest, I am not sure how useful it has been in our
hands. We see lousy-looking veins on ultrasound scanning
that actually will dilate up to something that is usable at
some point in the future. Our attitude basically is if we can
find something, even at the antecubital level, that can be
constructed into a 3-mm or 4-mm fistula, then it probably
should be done.
Dr Roy K. Greenberg (Rochester, NY). I share your
opinion regarding the relatively dismal results of the treat-
ment of thrombosed arteriovenous fistulas, and whenever
I see something on the schedule in our interventional
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suite, I often hope that there is an emergency elsewhere so
we can avoid dealing with it.
However, I do take issue on some of the cost data that
you presented. If I am correct in what I see in the cost
data, the majority of the cost was the result of either the
time spent in the operating room or the equipment. Most
of that equipment cost was probably related to the uroki-
nase and balloon cathethers, if that is correct.
There is a lot of literature to suggest that these proce-
dures can really be performed in less than 30 minutes and
also that the use of urokinase is optional. I do not believe
that there is a proven benefit with the use of urokinase in
conjunction with a mechanical device in this circumstance.
Mechanical devices, of course, can also be quite expen-
sive. In the absence of the data that support one thera-
peutic method over another, it comes down to a cost and
efficiency issue. I do not believe that this study accurately
defines the benefits of endovascular treatments.
Dr Dougherty. Well, I would tell you that the urokinase
certainly is a significant expense and that the issue of the use
of no urokinase and of simply trying to macerate clot with
an embolectomy catheter is something that other investiga-
tors have done. We have been nervous about doing that.
Just because you do not have a fatal pulmonary embolus in
your first 100 of these procedures does not mean it cannot
occur. It has occurred. It has been reported.
Second, 30 minutes is a very optimistic assessment.
Most of the reports, even in the radiology literature, have
had times in the neighborhood of 100 to 120 minutes.
But the time actually was not different between the two
groups. So, that did not account for any difference
between the two.
The balloons are fairly expensive, and I think that is
where the majority of the money is spent. And I think that
is the question: Is it worth it if the results are either equiv-
alent or maybe even a little bit inferior?
